level-one heading

ライター
データアナリスト
コンサルタント
製品開発者
研究者
Kolabtreeを選ぶ理由
開始はすばやく簡単です。初期費用はかかりません。
サービス依頼と専門家への見積依頼は無料です。
Kolabtree の作業範囲に同意する前に、専門家と要件を詳しく相談できます。
専門家と直接連携し、必要な成果を正しく得られます。
専門家を採用したらプロジェクトに資金を入れ、作業完了後に成果物を承認できます。
この専門家をプロジェクトに採用したいですか？ 見積もりを依頼 無料で。
プロフィール詳細
プロジェクトを作成
★★★★★
☆☆☆☆☆
Dr. Krishnaa U.に依頼
India

Clinical Pharmacologist | Clinical Research & Drug Development Expert | ICH-GCP, USFDA, EMA Compliance | Medical & Scien

プロフィール概要
専門分野
サービス
Writing Clinical Trial Documentation, Medical Writing
Research Market Research, Feasibility Study
Consulting Business Strategy Consulting
職務経験

Director

Krescent Medical Research Pvt Ltd

2月 2021 - 現在

学歴

PhD (Pharmacology)

Sunrise University

2月 2020 - 1月 2024

Master (Clinical Pharmacy)

NMIMS School of Pharmacy and Technology Management

8月 2009 - 8月 2011

認定資格
出版物
JOURNAL ARTICLE
e: Upadhye KS, Tayade P, Patidar H. Resmetirom: A promising treatment for no n-alcoholic steatohepatitis. Am J Pharmacother Pharm Sci 2025:010 .
Krishna U, Paritosh T, Hariom P, Narendra Y. The impact of gut microbiota in the development and management of diabetes. J Diabetol 2025;16:193-203 .
Upadhye KS, Patidar H. Anemia management strategies in diabetic kidney disease: A comprehensive review. J Diabetol 2025;16:93-101 .
Upadhye KS, Patidar H, Bamnia N, Yadav N. HbA1c reduction strategies: An overview of pharmacological interventions. Natl J Pharmacol Ther 2025;3:24-33 .
Krishna. S Upadhye, Paritosh Tayade, Hariom Patidar, Narendra Yadav (2025). Filgotinib: An Extensive Review of a Promising JAK Inhibitor in Rheumatoid Arthritis . Indian Journal of Rheumatology.
Upadhye, K.S., Tayade, P., Patidar, H., Yadav, N.(2025). Filgotinib: An Extensive Review of a Promising JAK Inhibitor in Rheumatoid Arthritis . Indian Journal of Rheumatology.
Upadhye, K.S., Patidar, H.(2025). Anemia Management Strategies in Diabetic Kidney Disease: A Comprehensive Review . Journal of Diabetology. 16. (2). Microsoft.AspNetCore.Mvc.Localization.LocalizedHtmlString 93-101.
Roy R, Vivek B, Krishna Upadhye (2024). EVALUATING PRESCRIPTION PATTERNS IN SURGICAL WARD: A CROSS-SECTIONAL ANALYSIS OF A RESEARCH CONDUCTED AT A SINGLE MEDICAL CENTER . EPRA International Journal of Multidisciplinary Research (IJMR).
(2024). EVALUATING THE APPREHENSIONS ABOUT THE EXCESSIVE UTILIZATION OF ANTI-SECRETORY MEDICATION CONSUMPTION . GJRA - GLOBAL JOURNAL FOR RESEARCH ANALYSIS.
Roy R, Vivek B, Krishna Upadhye (2024). TO EVALUATE THE PREVALENCE OF ANTISECRETORY MEDICATION USE AMONG HOSPITALIZED PATIENTS IN SURGERY WARD . EPRA International Journal of Research & Development (IJRD).
Krishna Upadhye, Dr. Uttam Kumar Aggarwal (2024). HEMATOLOGICAL DYNAMICS IN HEMODIALYSIS: A COMPREHENSIVE EXAMINATION OF PATIENTS WITH CHRONIC RENAL FAILURE IN A TERTIARY CARE HOSPITAL . EPRA International Journal of Multidisciplinary Research (IJMR).
(2024). FROM TREATMENT TO CHALLENGE: EXPLORING STEROID-INDUCED DIABETES MELLITUS – A COMPREHENSIVE CASE STUDY . PARIPEX - INDIAN JOURNAL OF RESEARCH.
Krishna Upadhye, “Anemia Prevalence and Its Correlations With Renal Function and Quality of Life in Diabetic Kidney Disease Patients," International Journal for Innovative Engineering and Management Research, Volume 12, Issue 01, Pages 979–984 (2023) .
Krishna Upadhye, “Exploring the Epidemiology and Association of Anemia in Diabetic Kidney Disease: A Comprehensive Analysis Of Patient Data," International Journal for Advanced Research in Science & Technology, Volume 12, Issue 7July 2022, https://www.ijarst.in/public/uploads/paper/730171698656914.pdf .
Filgotinib: An Extensive Review of a Promising JAK Inhibitor in Rheumatoid Arthritis @article{doi:10.1177/09733698251316343,author={Krishna. S Upadhye and Paritosh Tayade and Hariom Patidar and Narendra Yadav},title={Filgotinib: An Extensive Review of a Promising JAK Inhibitor in Rheumatoid Arthritis},journal={Indian Journal of Rheumatology},volume={0},number={0},pages={09733698251316343},year={0},doi={10.1177/09733698251316343},URL={https://doi.org/10.1177/09733698251316343 },eprint={https://doi.org/10.1177/09733698251316343 },abstract={This review aims to provide a comprehensive analysis of filgotinib, a selective Janus kinase 1 (JAK1) inhibitor, and its potential applications in the treatment of rheumatoid arthritis (RA). It assesses filgotinib’s efficacy, safety, and role compared to traditional disease-modifying antirheumatic drugs (DMARDs) and other JAK inhibitors. Authors conducted a systematic search of PubMed, Scopus and Google Scholar to identify relevant studies, including phase I, II, and III clinical trials. We extracted and synthesised data on efficacy end points (ACR20, ACR50, and ACR70), safety profiles, and long-term outcomes. We performed comparative analyses with traditional DMARDs and other JAK inhibitors. Filgotinib demonstrates high efficacy in RA management, with ACR20 response rates ranging from 70\% to 80\%, ACR50 from 40\% to 50\%, and ACR70 from 20\% to 30\%. It significantly reduces disease activity (as measured by DAS28-CRP) and improves physical function (as indicated by Health Assessment Questionnaire Disability Index [HAQ-DI] scores). Compared to traditional DMARDs, filgotinib offers superior efficacy and a favourable safety profile. In comparison to other JAK inhibitors, filgotinib’s selective JAK1 inhibition contributes to a similar or improved safety profile while maintaining high efficacy. Long-term data confirm its sustained benefits and manageable safety profile. Filgotinib is a promising treatment option for RA, offering significant benefits. Clinical trials have observed improvements in disease activity and quality of life. Its selective JAK1 inhibition and favourable safety profile make it a competitive alternative to both traditional DMARDs and other JAK inhibitors. Ongoing research into personalised medicine and emerging therapies will further define filgotinib’s role in RA management. }} . Indian Journal of Rheumatology.